NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Files NI 43-101 Technical Report Supporting Swanson Gold Project PEA
This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Executives Outline Positive PEA Results Plus Company’s Next Steps to Production in Investor Webinar
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid…
-
Versus Systems Inc. (NASDAQ: VS) Is ‘One to Watch’
Versus Systems operates a patented earned-rewards platform that integrates gamification with real-world incentives across digital…